The novel protein ADAMTS16 promotes gastric carcinogenesis by targeting IFI27 through the NF-κB signaling pathway

Tuoyang Li
Sun Yat-sen University Sixth Affiliated Hospital

Junyi Zhou
Sun Yat-sen University Sixth Affiliated Hospital

Yingming Jiang
Sun Yat-sen University Sixth Affiliated Hospital

Yandong Zhao
Sun Yat-sen University Sixth Affiliated Hospital

Jintuan Huang
Sun Yat-sen University Sixth Affiliated Hospital

Weiyao Li
Sun Yat-sen University Sixth Affiliated Hospital

Zhenze Huang
Sun Yat-sen University Sixth Affiliated Hospital

Zijian Chen
Sun Yat-sen University Sixth Affiliated Hospital

Xiaocheng Tang
Sun Yat-sen University Sixth Affiliated Hospital

Hao Chen
Sun Yat-sen University Sixth Affiliated Hospital

Zuli Yang (yangzuli@mail.sysu.edu.cn)

Research

Keywords: ADAMTS16, Gastric cancer, Tumor promoter, IFI27, NF-κB

Posted Date: July 8th, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1792512/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background  A disintegrin and metalloproteinase with thrombospondin motifs 16 (ADAMTS16) has been reported to be involved in the pathogenesis of solid cancers. However, its role in gastric cancer (GC) is unclear. In this study, the role of ADAMTS16 in gastric cancer was investigated.

Methods  The effects of ADAMTS16 on cell migration, invasion and proliferation were investigated by functional experiments in vivo and vitro. Targets of ADAMTS16 were identified using bioinformatics analysis co-immunoprecipitation, immunofluorescence and dual-luciferase reporter gene analysis assays. The expression of ADAMTS16 in GC was analyzed in public datasets. The expression of ADAMTS16 and its correlations with the clinical characteristics of GC were investigated by immunohistochemistry.

Results  Ectopic ADAMTS16 expression significantly promoted tumor cell migration, invasion, and growth. Bioinformatics analysis and western blotting showed that ADAMTS16 upregulated the IFI27 protein through the NF-κb pathway, which was confirmed by immunofluorescence and western blot. Dual-luciferase reporter gene analysis identified a binding site between P65 and IFI27 that may be directly involved in the transcriptional regulation of IFI27. IFI27 knockdown reversed the promoting effect of ADAMTS16 on cell invasion, migration and proliferation indicating that ADAMTS16 acts on GC cells by targeting the NF-κb/IFI27 axis. ADAMTS16 was associated with poor prognosis in clinical characteristics.

Conclusions  ADAMTS16 promotes cell migration, invasion and proliferation by targeting IFI27 through the NF-κB pathway and is a potential progressive and survival biomarker of GC.

Introduction

Gastric cancer (GC) is one of the most common cancers in the world, with more than 1 million new cases and an estimated 769,000 deaths in 2020, and ranks fifth and fourth in incidence and mortality, respectively, among malignant tumors worldwide (1). In China, as of 2015, the incidence and mortality rate of gastric cancer have jumped to the second only to lung cancer (2). In recent years, despite significant progress in surgery, chemotherapy, targeted therapy and biological therapy, the prognosis of cancer patients is remained poor (3, 4). Therefore, identifying novel factors and better insight into the mechanisms underlying gastric cancer would assist with the development of more effective diagnostic and/or therapeutic strategies.

ADAMTS16 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family which is including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif (5). Respective members of this family distinguish in the different number of C-terminal TS motifs, and some have unique C-terminal domains. It was expressed in human organ ubiquitously with a particularly abundant distribution in human fetus' lung, ovary, kidney and adults' brain(6). ADAMTS16 had been proved associating with human diseases. Pyun JA et al. discovered that ADAMTS16 plays a critical role in premature ovarian failure by interacting with thyroglobulin (7); Yao Y et al. revealed that ADAMTS16 promotes fibrosis and dysfunction of the
pressure-overloaded heart by acting TGF-beta (8). In recent studies, ADAMTS16 may be involved in tumor biological procession (9–12). In colorectal cancer (CRC), high expression of ADAMTS16 restrained cancer cell proliferation (9). Meanwhile, the mutation of ADAMTS16 altered the sensibility of ovarian cancer to platinum-based chemotherapy (9). However, rare is known about the detailed function and underlying molecular mechanism of ADAMTS16 in the pathology of GC.

In this study, we first aimed to comprehensively investigate the effects of ADAMTS16 and its associated mechanisms in GC. We next aimed to correlate ADAMTS16 with GC patient prognosis and clinicopathological features to determine whether it can be used as a prognostic predictor. Based on these findings, our goal is to develop a novel biomarker for future GC diagnosis and treatment.

**Methods**

**Cell lines**

Five human GC cell lines (MKN1, BGC803, HGC27, SGC7901, and AGS) and the human normal gastric mucosal cell lines GES1 and HEK293T were obtained from the Type Culture Collection Cell Bank of the Chinese Academy of Sciences Committee (Shanghai, China). AGS and HEK293T were cultured in F12-K and DMEM respectively, while the other cell lines were cultured in RPMI 1640 medium. All media were supplemented with 10% fetal bovine serum (FBS). The cells were incubated at 37°C in a humidified atmosphere containing 5% CO₂.

**Plasmid construction and transfection**

Expression plasmids for ADAMTS16 (NM_139056.4) and IFI27 (NM_001130080.3) were purchased from YouBio (China) and WZ Bioscience (China). The ADAMTS16 sequence was cloned into pCDH-GFP + Puro-3xFlag and pcDNA3.1(+) -Flag vectors. The IFI27 sequence was cloned into pLenti-CMV-MCS-SBP-3Flag-tRFP-F2A-Neo and pcDNA3.1(+) -HA vectors. The target sequences used for shRNA or siRNA gene-silencing plasmids were as follows: ADAMTS16, CCGGGAGGATAGCCGTAATGTTCTCGAGAACATTACGGCTATCCTCCTTTT; IFI27, CGGCTGGACTCTCCGGATTGACCTCGAGGTCAATCCGGAGAGTCCAGTTTTTG. The sequences were inserted into pLKO.1-TRC-copGFP-2A-PURO (WZ Biosciences, China). The amplified vectors were transformed into competent *Escherichia coli* DH5α cells (TSINGKE, China) and confirmed by sequencing. The vectors were isolated sequentially using an Endo-Free Plasmid Maxi Kit (Omega, USA). Transient transfection was performed using Lipofectamine 3000 reagent (Invitrogen, USA) according to the manufacturer’s instructions. For stable cell lines, 2 X 10⁵ GC cells were seeded on a 6-well plates. When the cells have grown to 70–80% confuence, replace fresh opti-men (Invitrogen, USA) medium without FBS and use the ADAMTS16 or shADAMTS16 virus infects the cells. After incubating for 72 h, the stable cells were obtained by puromycin screening. HGC27 and AGS were used for ADAMTS16 overexpression and IFI27 knockdown, whereas MKN-1 and SGC7901 were used for ADAMTS16 knockdown and IFI27 overexpression.
RNA extraction and quantitative real-time polymerase chain reaction

An RNA Quick Purification Kit (EZBioscience, China) was used to extract total RNA from cell lines and tissues following the manufacturer's protocol. Reverse transcription PCR and qRT-PCR were performed using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, California) and SYBR Green Master Mix Kit (Applied Biosystems, California) according to the manufacturer's instructions.

The qRT-PCR primer sequences were as follows: ADAMTS16, 5′-CCGGCCGGTACAAATTTTCG-3′ (forward), 5′-AACAGCAGCTCCACAATCAGT-3′ (reverse); GAPDH, 5′-GACAGTCAGCCGCATCTTCTT-3′ (forward), 5′-AATCCGTTGACTCGACCTTC-3′ (reverse); IFI27, 5′-TGCTCTCACCTCATCAGT-3′ (forward), 5′-CACAACCTCCTCCAATCACA-3′ (reverse).

Western bolt assay

Cells were lysed with T-PER Tissue Protein Extraction Reagent (Thermo Fisher, USA) containing protease and phosphatase inhibitors (ApexBio, USA). Nuclear and cytoplasmic proteins were separated using a Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime Biotechnology, China) according to the manufacturer's protocol. The protein concentration was quantitatively analyzed using a BCA Protein Quantitative Detection Kit (Servicebio, China) according to the manufacturer's instructions. Protein samples were separated on SDS-PAGE gel and transferred to PVDF membranes (Millipore, USA). The PVDF membranes were blocked with 5% skimmed milk at room temperature for 1 h and incubated overnight with the primary antibody at 4°C. They were then incubated with secondary antibodies at room temperature for 1 h and PVDF membranes detected using a Meilunbio Pico Chemiluminescent Substrate (Meilunbio, China). The membranes were then observed using a ChemiDoc Touch Imaging System (Bio-Rad, USA) and immunoblotted with the following primary antibodies: ADAMTS16 (OACD01415; 1:400; Avivasybio, USA), IFI27 (SAB1408588; 1:1000; Sigma, Germany), P65 (#8242; 1:1000; Cell Signaling Technology, USA), phospho-P65 (#3033; 1:1000; Cell Signaling Technology, USA), IkBa (#4814; 1:1000; Cell Signaling Technology, USA), and phospho-IkBa (#2859; 1:1000; Cell Signaling Technology, USA). GAPDH (60004-1-Ig; 1:10000; Proteintech, China) served as the internal control for total and cytoplasmic proteins, and H3 (384572; 1:1000; Zen BioScience, China) served as the internal control for nuclear proteins.

Migration and invasion assays

A transwell chamber with 8-µm pore size inserts (BD Biosciences, USA) covered or uncovered with Matrigel (Corning, USA) was used to evaluate GC cell migration and invasion. In brief, 4 × 10⁴ cells were resuspended in 100 µL of serum-free medium and plated in the upper chamber, and 700 µL of medium containing 10% FBS was added to the lower chamber. After adequate incubation at 37°C, the cells in the lower chamber were fixed with 4% paraformaldehyde and stained with crystal violet. Images of the cells in the lower chamber were captured under a microscope (Olympus, Japan), and cell counts were performed using ImageJ software (National Institutes of Health).
Wound healing assays

A total of $4 \times 10^4$ of stably transfected cells were seeded into a 12-well plate with Culture-Inserts 4 Well (Ibidi, Germany). After culturing for overnight, the well was removed, and the cells were incubated with a serum-free medium for another 24–48 h. Images of the wound healing process were captured at every 2 hour using Incucyte ZOOM (Essen BioScience, USA). To evaluate the cells’ wound healing ability, the percentage of wound closure was calculated using ImageJ (National Institutes of Health).

Colony formation assay

A total of $5 \times 10^2$ of stably transfected cells were placed in a 6-well plate for colony formation assay. After adequate incubation at 37°C for 10 to 14 days, the cells in the plate were fixed with 4% paraformaldehyde and stained with crystal violet. Cells in the 6-well plate were filmed by scanister (Canon, Japan) and calculated by ImageJ (National Institutes of Health).

Cell proliferation assays

A total of $1 \times 10^3$ of stably transfected cells were placed in a 96-well plate for proliferation assays. Incucyte ZOOM was used to capture images every 2 h during incubation for 96–120 h. Incucyte ZOOM was also used to calculate the cell occupation area in the plate according to the manufacturer’s instructions.

Apoptosis and cell cycle assays

Stable cells were cultured in 6-well plates at a density of $2 \times 10^6$ cells per well. After 48 h of culturing, the cells were harvested with or without a supernatant and stained using an Annexin V-APC/7-AAD apoptosis kit (MultiSciences, China) and a cell cycle staining kit (MultiSciences, China) according to the manufacturer’s instructions. Data were obtained using flow cytometry (Beckman Coulter, USA) and analyzed with FlowJo v10.0 (BD Biosciences, USA) or CytExpert v2.4 (Beckman Coulter, USA).

Tumor xenotransplantation model

All experiments were performed in accordance with the relevant guidelines and regulations of the animal care unit at Sixth Affiliated Hospital of Sun Yet-sen University. All vivo experiments were approved by the Ethics Committee of the Sixth Affiliated Hospital of Sun Yet-sen University. Vector/ ADAMTS16 HGC27 ($1 \times 10^6$) cells were injected subcutaneously into the left sides of female BALB/ c nude mice ($n = 5$; 6 weeks old). The tumor weight were measured on day 28 after injection. IHC and TUNEL analyses were performed on the collected subcutaneous tumors.

NF-κB inhibitor treatment assays

A total of $2 \times 10^5$ HGC27 or AGS cells in 6-well plates were treated with 10 mM BAY11-7082 (SF0011; Beyotime Biotechnology, China) for 24 h. Cell pellets were lysed with T-PER and detected by westernblot as described above.
RNA sequencing array and bioinformatics analysis

AGS-VECTOR/ADAMTS16 cells were analyzed using whole-transcriptome deep sequencing (RNA-Seq) on a BGISEQ-500 platform at the Beijing Genomics Institute. The data were analyzed using the database for annotation, visualization and integrated discovery (DAVID, https://david.ncifcrf.gov/) and gene set enrichment analysis (GSEA) v4.1.0.

Co-immunoprecipitation assays (Co-IP)

Stably ADAMTS16-overexpressing and control cells were lysed and extracted (abs955; Absin, China) according to the manufacturer’s instructions. ADAMTS16 and IκBα primary antibodies were used to pull down the proteins that interacted with each other at 4°C overnight. Protein detection was performed using western blot as described above after the extraction had been completed.

Immunofluorescence assays (IF)

A total of $4 \times 10^4$ cells were seeded into a 15-mm confocal dish after transient transfection with pCDNA3.1-ADAMTS16-Flag using Lipofectamine 3000 reagent as described above. After culturing for 24–48 h, the cells were fixed in 4% paraformaldehyde, and the cell membranes were penetrated with 0.25% Triton X100 for 15 min. The cells were then blocked with 1% BSA at room temperature for 30 min and incubated overnight with primary antibodies at 4°C. The primary antibodies were Flag (F1804; 1:1000; Sigma) and IκBα (#4814; 1:200; Cell Signaling Technology). The cells were then incubated with secondary antibodies at room temperature for one hour, and the nuclei were counterstained with DAPI for 5 min. Finally, the cells were observed, and images were captured using a confocal microscope (Carl Zeiss, Germany).

Dual-luciferase reporter assays

Plasmid pGL3-IFI27-WT/Mut1/Mut2 containing 1500–2000 bp upstream of two binding sites in the promoter region of IFI27 identified in public databases was purchased from IGEBIO (China). The pGL3-IFI27-WT/Mut1/Mut2, pRL-TK, and pCDNA3.1-P65-3xFlag plasmids were co-transfected into HGC27 and AGS cells using Lipofectamine 3000 according to the manufacturer's instructions. Using pGL3-IFI27-WT as a control, luciferase activity was measured using a Dual-Luciferase Reporter Assay System (Promega, USA) according to the manufacturer's protocol after 48h of culturing.

Public online cancer database analyses

The public database the cancer genome atlas (TCGA, https://www.cancer.gov/about-ncri/organization/ccg/research/structural-genomics/tcga) was used to search for differential ADAMTS16 expression in gastric tumors. GEPIA2 (http://gepia2.cancer-pku.cn/#index) was used for prognosis analysis of ADAMTS16 expression. The JASPAR database (https://jaspar.genereg.net/) was used to predict the binding site.

Patients and tissue samples
A total of 173 primary GC tissue samples were obtained from the Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, from December 2007 to March 2012. The samples were embedded in paraffin blocks to construct tissue microarrays (TMAs) for immunohistochemistry (IHC). The patients were followed up until death or until December 31, 2018. Patients who were lost to follow-up were excluded from the analysis. The interval between the date of surgery and the date of death or the last follow-up visit was defined as overall survival (OS). The interval between the date of surgery and the date of local recurrence and/or metastasis was defined as disease free survival (DFS).

**Immunohistochemistry**

ADAMTS16 expression was determined using a Biotin-Streptavidin-HRP-Detection-System (ZSGB-Bio, China) for IHC staining. Briefly, specimens were incubated overnight with primary rabbit antibodies against ADAMTS16 (OACD01415; 1:50; Avivasysbio, USA) at 4°C, and the primary antibody diluent was used as a negative control. Finally, specimens were developed with 3,3-diaminobenzidine (DAB) for 75 s and counterstained with hematoxylin. ADAMTS16 expression in sections was evaluated independently by two pathologists using a semiquantitative scoring system. The semiquantitative scoring system was defined as follows: 0 (negative staining), 1 (weak staining), 2 (moderate staining), and 3 (strong staining) was the intensity of IHC staining; 1 (1–25%), 2 (26–50%), 3 (51–75%), and 4 (76–100%) was the percentage of stained cells. We calculated IHC score by multiplying the intensity of staining with the percentage of positive cells. The median (8.25) was used as the cutoff score.

**Statistical analyses**

All data analyses were performed using IBM SPSS Statistics 21.0 software (IBM, USA). Figures were created using GraphPad Prism 7.0 software (GraphPad, USA). The results were expressed as means ± standard deviations. Comparisons between two groups were performed using Student’s t-test, the chi-squared test, or the Wilcoxon signed-rank test. The correlations between ADAMTS16 expression and clinicopathological characteristics were evaluated using the chi-squared test or Fisher’s exact test. Kaplan–Meier analysis (log-rank test) was performed to determine the correlation between ADAMTS16 expression and overall survival (OS) and disease free survival (DFS). Cox stepwise multivariate regression analysis of prognostic factors was performed. Values of $p < 0.05$ were considered statistically significant in all tests.

**Results**

**Ectopic ADAMTS16 expression promotes GC cell migration and invasion in vitro**

A series of in vitro assays was performed to elucidate the functions of ADAMTS516 in gastric cancer. We used western blotting to detect the endogenous expression of ADAMTS16 in GC cell lines (Fig. 1A).
HGC27 and AGS cell lines with low endogenous ADAMTS16 expression were selected to construct lentiviral vector–transfected cells stably overexpressing ADAMTS16 (Fig. 1B), while MKN1 and SGC7901 cell lines with high endogenous ADAMTS16 expression were selected to construct lentiviral vector–transfected cells with stable knockdown of ADAMTS16 (Fig. 1B). Transwell assays indicated that ADAMTS16 overexpression promoted HGC27 (Fig. 1C) and AGS (Fig. 1D) cells migration than control group. Similarly, invasion assays showed that ectopic expression of ADAMTS16 markedly enhanced cell invasive ability in both HGC27 (Fig. 1C) and AGS cells (Fig. 1D). Conversely, as predicted, the inhibition of ADAMTS16 expression decreased MKN1 (Fig. 1E) and SGC7901 (Fig. 1F) cells migration and invasion. Moreover, wound healing assays showed that ADAMTS16 overexpression promoted cell migration in GC cells HGC27 (Fig. 1G) and AGS (Fig. 1H), whereas ADAMTS16 downregulation inhibited it in MKN1 (Fig. 1I) and SGC7901 (Fig. 1J).

### Ectopic ADAMTS16 expression stimulates GC cell growth in vitro and vivo

To study the effect of ADAMTS16 on cell growth, we used the Incucyte ZOOM instrument to photograph the cell proliferation process and analyze the rate of cell proliferation, then conduct clone formation experiments simultaneously. ADAMTS16 overexpression significantly enhanced HGC27 and AGS clonogenicity compared to the controls (Fig. 2A). As expected, the proliferation rate significantly increased at 30 and 24 h, respectively (Fig. 2B). Conversely, ADAMTS16 knockdown reduced the clonogenic ability of MKN1 and SGC7901 (Fig. 2C), with significantly reduced proliferation rates at 18 and 6 h, respectively (Fig. 2D). To further explore the mechanism by which ADAMTS16 promotes cell growth, we analyzed cell cycle and apoptosis by flow cytometry. HGC27 and AGS overexpressing ADAMTS16 had more cells distributed in the G2/M phase than the control group (Fig. 2E). In contrast, in ADAMTS16 knockdown MKN1 and SGC7901 cell lines, the proportion of cells in the G2/M phase decreased compared with the control group (Fig. 2F). As expected, in apoptosis assays, ectopic expression of ADAMTS16 significantly decreased the proportion of apoptosis in HGC27 and AGS cells (Fig. 2G), while silencing expression of ADAMTS16 dramatically increased the proportion of apoptosis in MKN1 and SGC7901 cells (Fig. 2H). These results indicated that ADAMTS16 upregulation stimulates cell growth by promoting cell proliferation and inhibiting cell apoptosis.

The in vivo experiment results were consistent with the in vitro results. ADAMTS16 tumors grew faster and larger than vector tumors (Fig. 2I, J). Ki67 and Tunel showed that ADAMTS16 promoted tumor cell proliferation (Fig. 2K).

### ADAMTS16 promotes cell migration, invasion and proliferation via the NF-κB/IFI27 axis

To identify the ADAMTS16-mediated signal transduction pathways that promote GC cell growth and invasion, we performed RNA-Seq and bioinformatics analyses of AGS-vector/ADAMTS16 cells. A total of 806 genes changed their mRNA expression, of which 363 were upregulated (ADAMTS16/vector) and 443
were downregulated (Additional file 1: Fig. S1). The top 20 most differentially expressed genes are listed in Fig. 3A. Among them, the change in IFI27 was the most significant. Moreover, RT-PCR showed that the expression of IFI27 mRNA in HGC27 and AGS transfected with ADAMTS16 was higher than in the control group (Fig. 3B). In contrast, ADAMTS16 knockdown in MKN1 and SGC7901 suppressed IFI27 mRNA expression compared with the control group (Fig. 3B). These findings suggest that IFI27 may play an important role in ADAMTS16-induced promotion of GC cell growth, migration, and invasion. Furthermore, GSEA analysis showed that the HALLMARK_TNFA_SIGNALING_VIA_NFKB (Fig. 3C) pathway was enriched, suggesting that ADAMTS16 promotes cell migration, invasion and proliferation through the NF-κB/IFI27 axis.

To further examine how ADAMTS16 promotes GC cells carcinogenesis through the NF-κB/IFI27 axis, we performed a series of other analyses. We investigated the changes in the levels of NF-κB pathway proteins (IκBα, p-IκBα, P65, and p-P65). Western blotting demonstrated that compared with control cells, ADAMTS16 overexpression led to an increase in the expression of p-IκBα, p-P65, and IFI27 and a decrease in the expression of IκBα in HGC27 and AGS, no significant change in the expression of P65 (Fig. 3D). ADAMTS16 knockdown resulted in a decrease in the expression of p-IκBα, p-P65, and IFI27 and an increase in the expression of IκBα in MKN1 and SGC7901 (Fig. 3D). Furthermore, when the HGC27 and AGS (vector/ADAMTS16) cell lines were treated with the NF-κB pathway inhibitor BAY11-7082, the expression of IFI27 decreased (Fig. 3E). These results suggested that ADAMTS16 can activate the NF-κB pathway to upregulate IFI27.

In this study, ADAMTS16 overexpression upregulated nuclear phosphorylated P65, while ADAMTS16 knockdown significantly downregulated it (Fig. 3F). Co-immunoprecipitation revealed that ADAMTS16 can bind to IκBα (Fig. 3G, H). Immunofluorescence showed that ADAMTS16 was co-localized with IκBα in HGC27 and AGS cytoplasm (Fig. 3I). We also considered the possibility that P65 directly controls IFI27 gene transcription. We analyzed the transcription start site of IFI27 using the JASPAR database. The analysis identified two binding sites that P65 may occupy (Additional file 2: table. S1). P65 binding appears to activate the expression of IFI27. To investigate this possibility using dual-luciferase reporter assays, we produced the luciferase reporter constructs (pGL3-IFI27-WT, Mut1, and Mut2; Fig. 3J). The transcription levels of Mut1 and Mut2 were decreased in HGC27 and AGS cells compared with WT when co-transfected with pCDNA3.1-P65-3xFlag (Fig. 3K). This indicates that P65 might bind to the promoter region of IFI27 from −1618 to −1609 bp. These results suggest that ADAMTS16 induces the expression of IFI27 through the NF-κB pathway and possibly through direct transcriptional activation.

**IFI27 knockdown reverses ADAMTS16-induced promotion of GC cell growth and invasion**

To further investigate the role of IFI27 in ADAMTS16-mediated promotion of GC cell growth and invasion, we knocked down IFI27 in HGC27 and AGS cells stably overexpressing ADAMTS16 and induced IFI27 overexpression in ADAMTS16 knockdown MKN1 and SGC7901 cells. The expression of IFI27 was confirmed by using western blotting (Fig. 4A). As a result, the expression of ADAMTS16 was not affected...
by the expression of IFI27 (Fig. 4A), which further indicated that ADAMTS16 was located upstream of IFI27. Migration and invasion assays were performed to further investigate the effect of IFI27 expression on GC cell. IFI27 knockdown inhibited the migration and invasion of HGC27 and AGS cells (Fig. 4B, C). On the contrary, IFI27 overexpression promoted the migration and invasion of MKN1 and SGC7901 cells (Fig. 4D, E). As expected, Colony formation assay showed that knockdown of IFI27 significantly reversed colony formation ability of ADAMTS16 stable cell lines silencing IFI27 compared with control group cells (Fig. 4F). While overexpression of IFI27 significantly rescued colony formation ability of silencing ADAMTS16 stable cell lines MKN1 and SGC7901 (Fig. 4G).

**High expression ADAMTS16 is associated with poorer clinical characteristics**

By analyzing the expression of ADAMTS16 in a public dataset of GC patients, we found that the mRNA levels of ADAMTS16 were significantly increased in advanced-stage GC tissue compared with early-stage GC tissue (Fig. 5A). Meanwhile, the correlations between ADAMTS16 mRNA expression and the clinicopathological parameters of GC patients from are summarized in Additional file 3: Table. S2. In GC, ADAMTS16 mRNA expression was significantly correlated with age ($p = 0.004$), invasion depth ($p = 0.013$), lymph node metastasis ($p = 0.042$), distance metastasis stage ($p = 0.004$) and TNM stage ($p = 0.011$). Kaplan–Meier analysis indicated that high ADAMTS16 expression was associated with poor prognosis (Fig. 5B). To examine the impact of ADAMTS16 protein expression on GC progression, we evaluated associations between ADAMTS16 expression, and the survival data and clinicopathological features of GC patients. We next performed IHC analysis of TMAs of 176 human GC tissues. Representative results are shown in (Fig. 5C). All the samples that stained positively for ADAMTS16 exhibited a cytoplasmic localization, especially in those cases with high ADAMTS16 expression (Fig. 5C). Those GC patients with high expression of ADAMTS16 presented not only a shorter OS ($p < 0.01$) but also a shorter DFS ($p < 0.05$) than patients with low expression levels (Fig. 5D, E). Here, GC patients with high ADAMTS16 expression showed a mean OS of 69 months (95% CI = 57–80 months), while patients with low ADAMTS16 expression presented a mean OS of 90 months (95% CI = 81–101 months) (Fig. 1D). DFS of patients with high ADAMTS16 expression exhibited a mean of 70 months (95% CI = 57–82 months), while that of patients with low ADAMTS16 expression was significantly longer with a mean of 94 months (95% CI = 82–104 months) (Fig. 5E).

In order to validate the prognosis potential of ADAMTS16 expression with respect to other clinicopathological characteristics, we performed a Cox proportional hazards model for both OS and DFS of GC patients. Univariate analyses for overall survival revealed high expression of ADAMTS16 as a risk factor (hazard ratio (HR) = 2.691; 95% CI: 1.560–4.640; $p < 0.001$). Other clinicopathologic characteristics that associated significantly with shorter overall survival were TNM stage (HR = 2.185; 95% CI: 1.608–2.971; $p < 0.001$), perineural invasion (HR = 2.554; 95% CI: 1.377–4.737; $p = 0.003$) and vessel invasion (HR = 2.082; 95% CI: 1.204–3.603; $p = 0.009$) (Additional file 4: Table. S3). The clinical variable that associated significantly with reduced overall survival in the multivariate analysis was high expression of
ADAMTS16 (HR = 2.137; 95% CI: 1.128–4.051; p = 0.02) and TNM stage (HR = 1.751; 95% CI: 1.143–2.682; p = 0.01) (Additional file 4: Table S3). The univariate analysis for DFS also revealed that patients with high expression of ADAMTS16 presented higher risk of recurrence after surgery (HR = 1.902; 95% CI: 1.021–3.545; p = 0.043) (Additional file 5: Table S4). Other pathological characteristics that associated significantly with high risk of progression in the univariate analysis were TNM stage (HR = 3.206; 95% CI: 1.800–5.710; p < 0.001), perineural Invasion (HR = 3.552; 95% CI: 1.570–8.036; p = 0.002) and vessel Invasion (HR = 2.676; 95% CI: 1.345–5.324; p = 0.005) (Additional file 5: Table S4). In the multivariate analysis, only TNM stage remained statistically significant for higher risk of progression (HR = 2.696; 95% CI: 1.189–6.110; p = 0.018) (Additional file 5: Table S4). These results may indicate that ADAMTS16 is a potential biomarker to predict prognosis of GC patients.

In view of these results, we verified ADAMTS16 could be related to any of the pathological characteristics in our research (Table 1). High ADAMTS16 protein expression was significantly associated with lymph node metastasis (p = 0.025), vascular invasion (p = 0.016), and pTNM stage (p = 0.006) (Table 1). These results suggest the aberrant ADAMTS16 expression as a deleterious effect in GC patient and support previous survival results.
Table 1  
Correlation between the expression of ADAMTS5 and clinicopathological characteristics of GC patients (n = 176)

<table>
<thead>
<tr>
<th>Clinicopathological characteristics</th>
<th>Low ADAMTS16 (n = 87)</th>
<th>High ADAMTS16 (n = 89)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60 years</td>
<td>48 (55.2)</td>
<td>38 (42.7)</td>
<td>0.131</td>
</tr>
<tr>
<td>≥ 60 years</td>
<td>39 (44.8)</td>
<td>51 (57.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td>0.918</td>
</tr>
<tr>
<td>Male</td>
<td>59 (67.8)</td>
<td>61 (68.5)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>28 (32.2)</td>
<td>28 (31.5)</td>
<td></td>
</tr>
<tr>
<td><strong>Histologic type</strong></td>
<td></td>
<td></td>
<td>0.369</td>
</tr>
<tr>
<td>Tubular or papillary adeocarcinoma</td>
<td>69 (79.3)</td>
<td>76 (85.4)</td>
<td></td>
</tr>
<tr>
<td>Signet-ring cell carcinoma</td>
<td>14 (16.1)</td>
<td>7 (7.9)</td>
<td></td>
</tr>
<tr>
<td>Mucinous adeocarcinoma</td>
<td>3 (3.4)</td>
<td>5 (5.6)</td>
<td></td>
</tr>
<tr>
<td>Others&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1 (1.1)</td>
<td>1 (1.1)</td>
<td></td>
</tr>
<tr>
<td><strong>Differentiation</strong></td>
<td></td>
<td></td>
<td>0.728</td>
</tr>
<tr>
<td>Well</td>
<td>11 (12.6)</td>
<td>11 (12.4)</td>
<td></td>
</tr>
<tr>
<td>Moderately</td>
<td>11 (12.6)</td>
<td>8 (9.0)</td>
<td></td>
</tr>
<tr>
<td>Poor</td>
<td>65 (74.7)</td>
<td>70 (78.7)</td>
<td></td>
</tr>
<tr>
<td><strong>Invasion depth</strong></td>
<td></td>
<td></td>
<td>0.046</td>
</tr>
<tr>
<td>T1/T2</td>
<td>25 (28.7)</td>
<td>14(15.7)</td>
<td></td>
</tr>
<tr>
<td>T3/T4</td>
<td>62 (71.3)</td>
<td>75 (84.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Lymph node metastasis</strong></td>
<td></td>
<td></td>
<td>0.025</td>
</tr>
<tr>
<td>N0</td>
<td>29 (33.3)</td>
<td>16 (18.0)</td>
<td></td>
</tr>
<tr>
<td>N+</td>
<td>58 (66.7)</td>
<td>73 (82.0)</td>
<td></td>
</tr>
<tr>
<td><strong>Distant metastasis</strong></td>
<td></td>
<td></td>
<td>0.370</td>
</tr>
<tr>
<td>M0</td>
<td>79 (90.8)</td>
<td>77 (86.5)</td>
<td></td>
</tr>
</tbody>
</table>

Statistical analyses were performed by the Pearson χ2 test

<sup>a</sup>Others: hepatoid adeocarcinoma and squamous carcinoma
Clinicopathological characteristics | Low ADAMTS16 (n = 87) | High ADAMTS16 (n = 89) | P value |
--- | --- | --- | --- |
M1 | 8 (9.2) | 12 (13.5) | 0.006 |
TNM Stage | | | |
I/II | 37 (42.5) | 20 (22.5) | 0.006 |
III/IV | 50 (57.5) | 69 (77.5) | 0.552 |
Perineural Invasion | | | 0.552 |
Absent | 36.2 (57.4) | 28 (41.2) | |
Present | 63.8 (42.6) | 40 (58.8) | |
Vessel Invasion | | | 0.016 |
Absent | 39 (57.4) | 25 (36.8) | |
Present | 29 (42.6) | 43 (63.2) | |
Statistical analyses were performed by the Pearson χ² test

Discussion

GC is one of the most common malignant gastrointestinal tumors in China (2). Early diagnosis and advanced treatment strategies have made significant progress in the prognosis of GC patients (3, 13–15), but the mortality rate of GC is still high (16, 17). The factors promoting GC development are intricacy and further research on the underlying molecular mechanisms is urgently needed. Recently, novel proteins called ADAMTS proteins family have been discovered, and their expression was found in several types of tumors. ADAMTS protease family consists of 19 secreted zinc metalloproteases, whose substrates are primarily extracellular matrix (ECM) components (18). Accumulating evidence showed that ADAMTS proteins were essential to sustain embryonic development and tissue homeostasis (18). As a result, these factors may provide new perspectives in the clinical practice of gastric cancer. ADAMTS proteins have been found to have both pro-tumor and anti-tumor effects in various cancer settings (19, 20). ADAMTS12 acts as a cancer promoter in colorectal cancer via activating the Wnt/β-catenin signaling pathway in vitro (21). On the contrary, ADAMTS1 is an additional tumor suppressed protein, which was markedly decreased in lung, ovarian and breast cancer (22–24).

As a member of ADAMTS proteins family, ADAMTS16 was first revealed in the oncogene esophageal squamous cell carcinoma (12). However, there is no study about ADAMTS16 on GC until today whether have rarely revealed the latent molecular mechanisms. Firstly, we compared the ADAMTS16 expression in GC tissues by analyzing the data from TCGA and the results revealed that the mRNA levels of ADAMTS16
were significantly increased in advanced-stage GC tissue compared to early-stage GC tissue and high ADAMTS16 expression was associated with a poor prognosis.

To further explore the concrete role of ADAMTS16 in GC progression, we employed a series of in vitro function assays. In our current study, aberrant ADAMTS16 promoted GC cell in vivo and vitro by stimulating proliferation and restraining apoptosis. These findings were consistent with those previously reported that high expression of ADAMTS16 promoted cancer cell proliferation and invasion ability in vitro (12).

Then we screened ADAMTS16 downstream effector and pathways by using RNA-Seq. Among the significantly different signaling pathways activated by ADAMTS16, we focused on the NF-κB pathway. It is universally known that activating sustained proliferation and metastasis are the typical hallmarks of cancers. We figured out NF-κB related proteins including IkBα, p - IkBα (phospho - IkBα), P65 and p - p65 (phospho - P65) are influenced by ADAMTS16. Furthermore, ADAMTS16 was proved to interact with IkBα in cytoplasm and causing IkBα phosphorylation and degradation. Subsequently, the nuclear translocation of P65 was promoted. Meanwhile, we revealed that overexpression of ADAMTS16 promotes migration and invasion of GC cells in vitro, while knockdown decreases cell dispersion. Moreover, aberrant proliferation is one of the features of tumorigenesis. In our study, aberrant ADAMTS16 promoted GC cell in vivo and vitro by stimulating proliferation and restraining apoptosis. Taken together, we not only identified a novel prognostic biomarker for GC, but also a potential common genetic pathway between GC and ADAMTS16.

We further investigated the target genes of ADAMTS16 on GC cell lines and its downstream molecular pathway. RNA-Seq and bioinformatics analyses of AGS-vector/ADAMTS16 cells showed that IFI27 was the most significant of the top 20 most differentially expressed genes. IFI27 (Interferon Alpha Inducible Protein 27), a member of the FAM14 family, is stably induced by interferon (25) has been reported to regulate biological processes in numerous cancers (25–27). In GC, Deng R et al. Illustrated that IFI27 regulates tumor immunity via the canonical Wnt/β-catenin signaling pathway (28). However, we revealed that IFI27 is regulated by ADAMTS16 in GC. Furthermore, the specific NF-κB pathway inhibitor BAY11-7082 suppressed IFI27 expression, indicating that the activation of the NF-κB/IFI27 signaling cascade is regulated by ADAMTS16. As previous studies, P65 is associated with the occurrence and development of various tumors (29–32). The binding site between P65 and IFI27 was confirmed in our research. And then, we found that IFI27 overexpression restored the invasion, migration and proliferation abilities of GC cells to a certain extent. Therefore, we have reason to believe that ADAMTS16 promotes cell migration, invasion and growth through the NF-κB/IFI27 axis (Fig. 6). Accordingly, ADAMTS16 may function as a pro-tumor factor in GC development and progression in vivo that ADAMTS16 stimulated tumor growth in xenotransplantation model in this study.

In addition, the prognostic role of ADAMTS16 in gastric cancer was also confirmed. In this study, Clinicopathological analysis in this study revealed that abnormal overexpression of ADAMTS16 was associated with a poor prognosis in human gastric tumors. The cox proportional hazards model then
revealed that high ADAMTS16 expression is independent risk factor for poorer GC patient survival. Meanwhile, ADAMTS16 was significantly associated with the pathological characteristics including lymph node metastasis, local invasion and vascular invasion. Our findings suggested that ADAMTS16 might be a potential biomarker for predicting the prognosis of GC patients, which could help us better understand the mechanism of GC development.

Numerous studies in recent years have revealed that the NF-κB pathway can regulate epithelial-mesenchymal transition (EMT) (33, 34), influence the composition of the tumor microenvironment (TME) (33, 34), and alter tumor resistance to chemotherapeutic drugs (38–40), thereby affecting tumor progression. For example, cancer-associated fibroblasts derived IL-8 enhances chemoresistance via NF-κB activation in GC (41); gastric cancer cell-derived exosomes induce autophagy and pro-tumor activation of neutrophils via NF-κB by HMGB1/TLR4 interaction (42) and Alpha B-crystallin promotes GC cells invasion and metastasis via NF-κB-induced EMT. Similar reports have been reported on the drug resistance and epithelial-mesenchymal transition of IFI27 in ovarian cancer (43, 44). In this study, a series of functional experiments have confirmed the regulation of ADAMTS16/NF-κB/IFI27 signaling axis in the development of gastric cancer, suggesting that ADAMTS16 can be regarded as a potential target for the treatment of gastric cancer. Whether ADAMTS16/NF-κB/IFI27 regulates EMT, TME and tumor resistance still needs further study. In addition, ADAMTS family members belong to proteolytic enzymes of extracellular matrix (ECM) and secretory proteins (43, 44). In recent years, the degradation of ECM has also been shown to promote tumor development (45, 46). But the role of ADAMTS16 in gastric cancer remains unclear. Therefore, it is urgent for us to further study ADAMTS16 to promote the occurrence and development of GC, expecting to play a certain guiding role in the strategy of gastric cancer treatment.

**Conclusion**

This study indicates that ADAMTS16 plays a role as a tumor promoter and its upregulation is associated with a poor prognosis in GC. ADAMTS16 promotes GC cell invasion, migration, and proliferation. In terms of mechanism, ADAMTS16 interacts directly with IκBα cytoplasm to promote IκBα phosphorylated degradation and then P65 has been released into the nucleus, resulting in IFI27 upregulation, thereby promoting GC cell migration, invasion and proliferation. Based on the clinical and biological significance of the ADAMTS16/NF-κB/IFI27 axis, ADAMTS16 can be considered as a GC prognostic biomarker and a potential therapeutic target.

**Abbreviations**
<table>
<thead>
<tr>
<th>ADAMTS</th>
<th>A Disintegrin and Metalloproteinase with Thrombospondin motifs</th>
</tr>
</thead>
<tbody>
<tr>
<td>GC</td>
<td>Gastric cancer</td>
</tr>
<tr>
<td>IHC</td>
<td>Immunohistochemistry</td>
</tr>
<tr>
<td>Co-ip</td>
<td>Co-immunoprecipitation</td>
</tr>
<tr>
<td>IF</td>
<td>Immunofluorescence</td>
</tr>
<tr>
<td>IFI27</td>
<td>Interferon Alpha Inducible Protein 27</td>
</tr>
<tr>
<td>NF-kb</td>
<td>Nuclear factor-kappa B</td>
</tr>
<tr>
<td>TCGA</td>
<td>The cancer genome atlas</td>
</tr>
<tr>
<td>TMA</td>
<td>Tissue microarray</td>
</tr>
<tr>
<td>DAB</td>
<td>Diaminobenzidine</td>
</tr>
<tr>
<td>FBS</td>
<td>Fetal bovine serum</td>
</tr>
<tr>
<td>WB</td>
<td>Western blotting</td>
</tr>
<tr>
<td>DAVID</td>
<td>Database for annotation, visualization and integrated discovery</td>
</tr>
<tr>
<td>GSEA</td>
<td>Gene set enrichment analysis</td>
</tr>
<tr>
<td>ECM</td>
<td>Extracellular matrix</td>
</tr>
<tr>
<td>EMT</td>
<td>Epithelial-mesenchymal transition</td>
</tr>
<tr>
<td>TME</td>
<td>Tumor microenvironment</td>
</tr>
</tbody>
</table>

**Declarations**

**Ethical approval and consent to participate**

This study was approved by the Human Research Ethics Committee of the Sixth Affiliated Hospital of Sun Yet-sen University. All animal experiments were approved by the Laboratory Animal Ethics Committee of the Sixth Affiliated Hospital of Sun Yet-sen University.

**Consent for publication**

All authors give consent for publication.

**Availability of data and materials**

All the data and material in this study can be request from the corresponding author reasonably.
Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by grants from the National Key Clinical Discipline, the National Natural Science Foundation of China (Grant Nos 81772594, 81802322, and 81902949), the Science and Technology Program of Guangzhou (Grant No. 201803010095), and the Natural Science Foundation of Guangdong Province, China (Grant Nos 2020A1515011362 and 2022A1515010262).

Author’s contribution Conceptualization

ZLY and HC conceived and designed the study. TYL, JYZ, YMJ, HC, YDZ, JTH, WYL, ZZH, ZJC and XCT performed the experiments. TYL and YJZ performed qPCR, cell culture. YDZ performed H&E and IHC. YTL, JYZ, YMJ and HC conducted WB and animal experiments. TYL and YMJ co-immunoprecipitation assays. TYL, JYZ, HC and WYL performed Immunofluorescence assay and evaluation. TYL and YMJ performed Dual-luciferase reporter assays. HZZ, ZJC and XCT interpreted and analyzed the data. TYL, JYZ and ZLY wrote and reviewed the manuscript. All authors have read and approved the final manuscript.

Acknowledgements

The authors sincerely thank Xihu Yu and Tao Yang for providing technical assistance.

Author details

1Department of Gastrointestinal Surgery, the Sixth Affiliated Hospital, Sun Yat-sen University, 26 Yuancun Erheng Rd, Guangzhou, Guangdong, 510655, China. 2Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, the Sixth Affiliated Hospital, Sun Yat-sen University, 26 Yuancun Erheng Rd, Guangzhou, Guangdong, 510655, China.

References


Figures
ADAMTS16 promotes GC cell migration and invasion in vitro. A Detection of ADAMTS16 protein expression in five GC cell lines (MKN1, BGC823, HGC27, SGC7901, and AGS) and normal gastric epithelial cells (GES1) by western blotting. B The expression of ADAMTS16 in stably transfected cells was confirmed by western blotting. C–F Transwell assays were used to assess cell migration and invasion in the indicated cell lines (original magnification: 200x). G–J Representative images of wound healing.
assays at indicated times (original magnification: 200×). The data are shown as means ± standard deviations. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Figure 2

Effects of ADAMTS16 expression on GC cell adhesion and growth. A–D Representative colony formation assay using monolayer culture to quantitative analysis and incucyte zoom was used to capture images
at different time points to calculate the cell occupation area in the plate. **E–F** Flow cytometry showed that ADAMTS16 expression in GC cell lines induced G2/M phase arrest. **G–H** Flow cytometry was used to reveal the effects of ADAMTS16 expression on GC cell apoptosis arrest. **I–K** Effect of ADAMTS16 expression on tumor growth in nude mice and representative immunohistochemistry images of ADAMTS16, Ki67 and tunel in tumor tissues. The data are shown as means ± standard deviations. $* p < 0.05$, $** p < 0.01$, $*** p < 0.001$, $**** p < 0.0001$
Figure 3

Ectopic ADAMTS16 expression promotes GC cell invasion and migration via the NF-κB/IFI27 axis. A Heat map analysis showed altered genes in AGS-vector and AGS-ADAMTS16 cells. B Quantitative real-time polymerase chain reaction was performed to detect IFI27 mRNA expression in stably ADAMTS16-expressing cell lines. C Gene Set Enrichment Analysis showed enrichment of ADAMTS16-associated genes in the HALLMARK_TNF_SIGNALING–VIA_NFKB pathway. D Western blotting of phospho-IκBα, IκBα, phospho-P65, P65, and IFI27 in stably transfected GC cell lines. E Western blotting was performed to analyze the expression of IFI27 in stably transfected HGC27 and AGS cells treated with or without 10 μM BAY11-7082 (NF-κB inhibitor) for 24 h. F Western blotting showed that ADAMTS16 overexpression promoted the phosphorylation of P65 in the nucleus. G–H Co-immunoprecipitation assays revealed that ADAMTS16 interacted with IκBα in HGC27 and AGS. I Immunofluorescence assays revealed that ADAMTS16 was co-localized with IκBα in HGC27 and AGS cell cytoplasm. J Schematic representation of IFI27 promoter organization and the corresponding luciferase reporter constructs pGL3-IFI27-WT, Mut1, and Mut2. Transcriptional start site, E1 exon1, and Luc luciferase. The blue and red bars indicate the binding sites of P65, including original and mutated sequences. K Dual-luciferase reporter assays were performed to analyze the activity of the pGL3-IFI27-WT, Mut1, and Mut2 constructs in HGC27 and AGS cells. The data are shown as means ± standard deviations. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
IFI27 protein knockdown reverses ADAMTS16-induced GC cell promotion. **A** Western blotting of IFI27 in stably ADAMTS16-transfected HGC27 and AGS cells and stably knockdown ADAMTS16–transfected MKN1 and SGC7901 cells. **B–E** Transwell assays were performed to assess cell migration and invasion in the indicated cell lines (original magnification: 200×). **F–G** Colony formation assays were performed to
assess cell colony formation and proliferation ability in the indicated cell lines. The data are shown as means ± standard deviations. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$

Figure 5

ADAMTS16 is upregulated in gastric cancer (GC) and is associated with a poor prognosis. A ADAMTS16 mRNA expression in advanced-stage GC tissue was higher than in early-stage GC tissue in TCGA. B

C. Gastric cancer tissue

D. E.
GEPIA2 Kaplan–Meier plot of the effect of ADAMTS16 gene expression on GC patient survival. C Representative immunohistochemical staining for ADAMTS16 in GC. D Kaplan–Meier survival curves of GC patients on ADAMTS16 expression. The data are shown as means ± standard deviations. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Extracellular

Cytoplasm

ADAMTS16

IkBα

P65

ADAMTS16

IkBα

P65

IkBα

P65

Degraded IkBα

Nucleus

Target gene of NF-κB signaling pathway

P65

P65

IFI27

Invasion

Proliferation

Migration

Figure 6

Model for the mechanism of ADAMTS16 in the development of GC.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- WBuncorped.tif
- figures1.tif
- tableS1.docx
• tableS2.docx
• tableS3.docx
• tableS4.docx